Cyclin D1 G870A polymorphism and lung cancer risk: A meta-analysis

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1467-1476

  Liu, Jianming ^a,b   Liao, Qiande ^b   Zhang, Yangde ^b   Sun, Shenghua ^a   Zhong, Caigao ^a   Liu, Xinmin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Cyclin D1; Gene polymorphism; Lung cancer; Meta analysis

Indexed keywords

CYCLIN D1;

ARTICLE; CANCER RISK; CYCLIN D1 GENE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LUNG CANCER; PRIORITY JOURNAL;

EID: 84868102149     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0397-0     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-92.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367-80.
4. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399-408.
5. Steliga MA, Dresler CM. Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. Surg Oncol Clin N Am. 2011;20:605-18.
6. Yokota J, Shiraishi K, Kohno T. Genetic basis for susceptibility to lung cancer: recent progress and future directions. Adv Cancer Res. 2010;109:51-72.
7. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-7.
8. Herber B, Truss M, Beato M, Muller R. Inducible regulatory elements in the human cyclin d1 promoter. Oncogene. 1994;9:1295-304.
9. Sherr CJ. Mammalian g1 cyclins. Cell. 1993;73:1059-65.
10. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222-31.
11. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin d1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620-8.
12. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin d1 isoform, cyclin d1b, is a nuclear oncogene. Cancer Res. 2003;63:7056-61.
13. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES. Cyclin d1 splice variants. Differential effects on localization, rb phosphorylation, and cellular transformation. J Biol Chem. 2003;278:30339-47.
14. Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC. Cyclin d1 (ccnd1) a870g gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (nsclc) patients. Lung Cancer. 2006;51:303-11.
15. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007;13:5974-81.
16. Qiuling S, Yuxin Z, Suhua Z, Cheng X, Shuguang L, Fengsheng H. Cyclin d1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003;24:1499-503.
17. Hung RJ, Boffetta P, Canzian F, Moullan N, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, Landi S, Gemignani F, Hall J, Brennan P. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res. 2006;66:8280-6.
18. Sobti RC, Kaur P, Kaur S, Singh J, Janmeja AK, Jindal SK, Kishan J, Raimondi S. Effects of cyclin d1 (ccnd1) polymorphism on susceptibility to lung cancer in a north Indian population. Cancer Genet Cytogenet. 2006;170:108-14.
19. Hsia TC, Liu CJ, Lin CH, Chang WS, Chu CC, Hang LW, Lee HZ, Lo WC, Bau DT. Interaction of ccnd1 genotype and smoking habit in Taiwan lung cancer patients. Anticancer Res. 2011;31:3601-5.
20. Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297-303.
21. Petitti DB. Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine (2nd ed). New York: Oxford University Press; 2000.
22. Sotiriadis A, Makrigiannakis A, Stefos T, Paraskevaidis E, Kalantaridou SN. Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol. 2007;109:1146-55.
23. Su MT, Lin SH, Chen YC. Genetic association studies of angiogenesis- and vasoconstriction-related genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod Updat. 2011;17:803-12.
24. Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840-8.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
28. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
29. Thompson SG, Higgins J. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559-73.
30. A Tobias Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15-17.
31. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, Mountain JL, Perez-Stable EJ, Sheppard D, Risch N. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170-5.
32. Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health. 2004;58:441-5.
33. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
35. Wang R, Zhang JH, Li Y, Wen D, Wei L. The association of cyclin d1(a870g)polymorphism with susceptibility to lung cancer in northern Chinese population. Tumor. 2003;23:364-6. Article in Chinese.
36. Li QP, Deng YJ, Xiao CJ, Yang HS. Comparative study of polymorphism of cyclin dl gene in patients with non small cell lung cancer from Xuanwei and Kunming. Shandong Yi Yao. 2009;49:1-3. Article in Chinese.
37. Buch S, Zhu B, Davis AG, Odom D, Siegfried JM, Grandis JR, Romkes M. Association of polymorphisms in the cyclin d1 and xpd genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005;42:222-8.
38. Wang Q, Jiang YX, Li GF, Liu X, Wang WW, Deng J, Chen N. The relationship between the cyclin d1(ccndi)a870g gene polymorphism and non small cell lung cancer in Yunnan. Med Philos. 2008;29:36-8. Article in Chinese.
39. Ma H, Chen J, Pan S, Dai J, Jin G, Hu Z, Shen H, Shu Y. Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population. Lung Cancer. 2011;73:32-7.
40. Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, Ozcelik H. Cyclin d1 pro241pro (ccnd1-g870a) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomark Prev. 2008;17:2773-81.
41. Betticher DC, Heighway J, Thatcher N, Hasleton PS. Abnormal expression of ccnd1 and rb1 in resection margin epithelia of lung cancer patients. Br J Cancer. 1997;75:1761-8.
42. Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin d1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011;4:779-82.
43. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin d1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55:1-14.
44. Olding LB, Thurin J, Svalander C, Koprowski H. Expression of gastrointestinal carcinoma-associated antigen (gica) detected in human fetal tissues by monoclonal antibody ns-19-9. Int J Cancer J Int Du Cancer. 1984;34:187-92.
45. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin d as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558-72.
46. Peters J, Mengersen K. Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof. 2008;31:370-89.
47. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209-17.
48. Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y. A meta-analysis of tp53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer. 2009;66:15-21.